CNS Depressants: Alcohol and Nicotine

Ethanol acts as a GABA agonist and inhibits glutamate's excitatory actions in the central nervous system. This dual mechanism reduces neural excitation, leading to impaired motor control, decreased inhibitions, and sedation. At higher doses, ethanol can cause severe consequences including coma and respiratory depression due to its zero-order elimination kinetics.

Chronic ethanol use leads to tolerance and physical dependence. Abrupt cessation triggers life-threatening withdrawal symptoms known as delirium tremens, including anxiety, tremors, seizures, tachycardia, sweating, hallucinations, and convulsions. These symptoms necessitate immediate medical intervention and long-term addiction treatment to prevent serious complications.

Alcohol dependence treatment involves detoxification and pharmacotherapy. Benzodiazepines manage withdrawal symptoms, while disulfiram creates unpleasant reactions to alcohol consumption to deter drinking. Naltrexone, a competitive opioid antagonist, and acamprosate, an NMDA regulator, help reduce alcohol cravings through distinct neurochemical mechanisms.

Nicotine exhibits dose-dependent dual action on the CNS. At low doses, it stimulates nicotinic acetylcholine receptors, triggering dopamine release and producing euphoria, improved attention, and relaxation. At high doses, nicotine causes ganglionic blockade, producing depressant effects and raising health concerns about its widespread use in tobacco products.

Nicotine withdrawal causes irritability, restlessness, sleep problems, difficulty concentrating, and intense cravings. These symptoms reflect the high addictive potential of nicotine and its rapid absorption through multiple routes including smoking and skin contact. Withdrawal management requires pharmacological support and behavioral approaches to sustain abstinence.

Varenicline, a partial nicotinic receptor agonist, alleviates nicotine withdrawal symptoms by partially activating nicotinic acetylcholine receptors. This reduces cravings and withdrawal discomfort while blocking nicotine's rewarding effects if relapse occurs. Varenicline is often combined with behavioral approaches for comprehensive nicotine deaddiction therapy.

Cross-tolerance between alcohol and sedatives like benzodiazepines exacerbates the dangers of concurrent use. Both substances act as CNS depressants through similar mechanisms, and combined use increases risks of severe respiratory depression, overdose, and death. This interaction requires careful medical monitoring during alcohol detoxification and treatment.